UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 ___________________________________
 FORM 10-K/A
 Amendment No. 1
 ___________________________________
 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2024
 OR

 o
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from ________ to ________
 Commission file number 001-04321
 ___________________________________

 PROCEPT BIOROBOTICS CORPORATION
 (Exact name of registrant as specified in its charter)
 ___________________________________

 Delaware
 3841
 26-0199180

 (State or other jurisdiction of incorporation or organization)

 (Primary Standard Industrial Classification Code Number)

 (I.R.S. Employer Identification No.)

 150 Baytech Drive
 San Jose, CA

 95134

 (Address of Principal Executive Offices)
 (Zip Code)

 (650) 232-7200
 Registrant's telephone number, including area code
 Securities registered pursuant to Section 12(b) of the Act:

 Title of each class
 Trading Symbol(s)
 Name of each exchange on which registered

 Common stock, $0.00001 par value per share
 PRCT
 Nasdaq Global Market

 Securities registered pursuant to Section 12(g) of the Act: None
 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No o
 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes o No x
 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large accelerated filer
 x

 Accelerated filer

 o

 Non-accelerated filer
 o

 Smaller reporting company

 o

 Emerging growth company

 o

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. x
 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).
 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x
 As of June 30, 2024, the aggregate market value of shares held by non-affiliates of the Registrant (based upon the closing sale prices of such shares on the Nasdaq Global Market on June 30, 2024) was approximately $ 3.1 billion. Shares of common stock held by each executive officer, director, and their affiliated holders have been excluded in that such persons may be deemed to be affiliates. The determination of affiliate status for this purpose is not necessarily a conclusive determination for any other purpose.
 The registrant had outstanding 54,818,700 shares of common stock as of February 20, 2025.
 DOCUMENTS INCORPORATED BY REFERENCE
 Portions of the registrant's definitive Proxy Statement for its 2025 Annual Stockholders' Meeting, to be filed within 120 days of the registrant's fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K.

 EXPLANATORY NOTE
 PROCEPT BioRobotics Corporation (the "Company") is filing this Amendment No. 1 on Form 10-K/A (this "Amendment") to amend the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the "Original Filing"), which was originally filed with the U.S. Securities and Exchange Commission (the "SEC") on February 27, 2025 (the "Original Filing Date"). The sole purpose of this Amendment is to supplement the Exhibits contained in Item 15(a) of Part IV of the Original Filing to include Exhibit 19.1, the Company's Insider Trading Compliance Policy and Procedures, which was inadvertently omitted in the Original Filing.
 This Amendment is an exhibit-only filing. Except as described above, no changes have been made to the Original Filing and this Amendment does not modify, amend, or update in any way any of the financial or other information contained in the Original Filing. This Amendment does not reflect events that may have occurred subsequent to the Original Filing Date. Accordingly, this Amendment should be read in conjunction with the Original Filing and the Company's other filings with the SEC.
 Pursuant to Rule 12b-15 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), currently dated certifications are filed herewith as exhibits to this Amendment pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act under Item 15(a) of Part IV hereof. Because no financial statements have been included in this Amendment and this Amendment does not contain any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.

 Item 15. Exhibits, Financial Statement Schedules

 (a)Exhibits.

 Exhibit No.
 Exhibit Description

 3.1
 Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K (File No. 001-40797) filed on September 21, 2021)

 3.2
 Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the registrant's Current Report on Form 8-K (File No. 001-40797) filed on September 21, 2021)

 4.1
 Description of PROCEPT BioRobotics Corporation's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.1 to the registrant's annual report on Form 10-K for the year ended December 31, 2021 (File No. 001-40797))

 10.1+
 Offer Letter, by and between the Registrant and Reza Zadno, Ph. D., dated as of January 31, 2020 (incorporated by reference to Exhibit 10.1 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.2+
 Offer Letter, by and between the Registrant and Kevin Waters, dated as of August 7, 2018 (incorporated by reference to Exhibit 10.2 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.3+
 Offer Letter, by and between the Registrant and Hisham Shiblaq, dated as of March 21, 2019 (incorporated by reference to Exhibit 10.3 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.4+

 Offer Letter, by and between the Registrant and Alaleh Nouri, dated as of May 15, 2018 (incorporated by reference to Exhibit 10.18 to the registrant's quarterly report on Form 10-Q for the period ended March 31, 2023 (File No. 001-40797))

 10.5+

 Amended and Restated 2008 Stock Plan (incorporated by reference to Exhibit 10.4 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.5(a)+

 Form of Stock Option Agreement under the Amended and Restated 2008 Stock Plan (incorporated by reference to Exhibit 10.4(a) to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.6
 Form of Indemnification and Advancement Agreement (incorporated by reference to Exhibit 10.5 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.7
 Amended and Restated Exclusive License Agreement, by and between the Registrant and AquaBeam LLC, dated as of September 13, 2019 (incorporated by reference to Exhibit 10.6 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.8

 Not used.

 10.9
 Lease, by and between the Registrant and 150-180 Baytech Drive CA Owner, LLC, dated December 31, 2021 (incorporated by reference to Exhibit 10.9 to the registrant's annual report on Form 10-K for the year ended December 31, 2021 (File No. 001-40797))

 10.10+
 Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.1 to the registrant's quarterly report on Form 10-Q for the period ended March 31, 2024 (File No. 001-40797))

 10.11+
 2021 Equity Incentive Award Plan (incorporated by reference to Exhibit 10.11 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.11(a)+
 Form of Stock Option Agreement under the 2021 Equity Incentive Award Plan (incorporated by reference to Exhibit 10.11(a) to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.11(b)+
 Form of Restricted Stock Unit Agreement under the 2021 Equity Incentive Award Plan (incorporated by reference to Exhibit 10.11(b) to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.11(c)+
 Form of Performance Stock Unit Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the registrant's quarterly report on Form 10-Q for the period ending March 31, 2024 (File No. 001-40797))

 10.12+
 Amended and Restated 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.1 to the registrant's quarterly report on Form 10-Q for the period ending September 30, 2023 (File No. 001-40797))

 10.13+
 Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Reza Zadno, Ph. D., dated September 17, 2021 (incorporated by reference to Exhibit 10.13 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.14+
 Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Kevin Waters, dated September 17, 2021 (incorporated by reference to Exhibit 10.14 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.15+
 Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Hisham Shiblaq, dated September 17, 2021 (incorporated by reference to Exhibit 10.15 to the registrant's registration statement on Form S-1 (File No. 333-258898))

 10.16+
 Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Alaleh Nouri, dated September 17, 2021 (incorporated by reference to Exhibit 10.19 to the registrant's quarterly report of Form 10-Q for the period ended March 31, 2023 (File No. 001-40797))

 10.17
 Loan and Security Agreement, by and among Canadian Imperial Bank of Commerce, the Registration, and each Borrower and Guarantor from time to time, dated as of October 6, 2022 (incorporated by reference to Exhibit 10.1 to the registrant's current report on Form 8-K filed on October 10, 2022 (File No. 001-40797))

 10.17(a)
 First Amendment to Loan and Security Agreement, by and between Canadian Imperial Bank of Commerce and the Registrant, dated June 1, 2023 (incorporated by reference to Exhibit 10.1 to the registrant's current report on Form 8-K filed on June 2, 2023 (File No. 001-40797))

 10.18#
 Confidential Exclusive Patent License and Covenant Not to Sue, by and between the Registrant and HydroCision, Inc., dated March 14, 2019 (incorporated by reference to Exhibit 10.7(d) to the registrant's annual report on Form 10-K for the year ended December 31, 2022 (File No. 001-40797))

 19.1*
 Insider Trading Compliance Policy and Procedures.

 21.1
 List of subsidiaries of the Registrant

 23.1
 Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm, (incorporated by reference to Exhibit 23.1 to the registrant's annual report on Form 10-K for the year ended December 31, 2024 (File No. 001-40797))

 24.1
 Power of Attorney (included on signature page).

 31.1*

 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 31.2*

 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.1
 Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (furnished with the registrant's annual report on Form 10-K for the year ended December 31, 2024 (File No. 001-40797))

 32.2
 Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (furnished with the registrant's annual report on Form 10-K for the year ended December 31, 2024 (File No. 001-40797))

 97.1
 Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the registrant's annual report on Form 10-K for the year ended December 31, 2023 (File No. 001-40797))

 101.INS

 101.SCH

 101.CAL

 101.DEF

 101.LAB

 101.PRE

 __________________
 *Filed herewith.
 + Indicates management contract or compensatory plan.
 # Certain portions of this Exhibit (indicated by "[***]") have been omitted pursuant to Regulation S-K, Item (601)(b)(10)

 Signatures
 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 PROCEPT BIOROBOTICS CORPORATION

 Date:
 April 11, 2025
 By:
 /s/ Reza Zadno

 Name:
 Reza Zadno, Ph. D.

 Title:
 Chief Executive Officer